Sarepta Therapeutics, Inc. vs Perrigo Company plc: SG&A Expense Trends

SG&A Expense Trends: A Tale of Two Companies

In the ever-evolving landscape of the pharmaceutical industry, understanding the financial strategies of key players is crucial. Over the past decade, Perrigo Company plc and Sarepta Therapeutics, Inc. have showcased distinct trends in their Selling, General, and Administrative (SG&A) expenses.

Perrigo, a global leader in over-the-counter health products, has consistently maintained higher SG&A expenses, peaking at approximately $1.27 billion in 2023. This represents a 47% increase from 2014, reflecting their expansive market strategies and operational scale. In contrast, Sarepta, a pioneer in genetic medicine, has seen a dramatic rise in SG&A expenses, surging by over 870% from 2014 to 2023. This growth underscores their aggressive investment in research and market penetration.

These trends highlight the contrasting approaches of a mature market leader and an innovative disruptor, offering valuable insights into their strategic priorities and market positioning.